121 related articles for article (PubMed ID: 25333735)
1. The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer: A National Study.
Cárdenas-Ramos SG; Alcázar-González G; Reyes-Cortés LM; Torres-Grimaldo AA; Calderón-Garcidueñas AL; Morales-Casas J; Flores-Sánchez P; De León-Escobedo R; Gómez-Díaz A; Moreno-Bringas C; Sánchez-Guillén J; Ramos-Salazar P; González-de León C; Barrera-Saldaña HA
Am J Clin Oncol; 2017 Jun; 40(3):274-276. PubMed ID: 25333735
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
3. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
4. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab Might Be Detrimental to Metastatic Colorectal Cancer Patients with KRAS Codon 12 Mutations.
Liang YH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Hung JS; Tseng LH; Lin LI; Chang YL; Cheng AL; Yeh KH
Anticancer Res; 2015 Jul; 35(7):4207-14. PubMed ID: 26124380
[TBL] [Abstract][Full Text] [Related]
7. Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes.
Zekri J; Al-Shehri A; Mahrous M; Al-Rehaily S; Darwish T; Bassi S; El Taani H; Al Zahrani A; Elsamany S; Al-Maghrabi J; Sadiq BB
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218784
[TBL] [Abstract][Full Text] [Related]
8. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
10. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
11. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
[TBL] [Abstract][Full Text] [Related]
12. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T
Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
Veldore VH; Rao MR; Prabhudesai SA; Tejaswi R; Kakara S; Pattanayak S; Krishnamoorthy N; Tejaswini BN; Hazarika D; Gangoli A; Rahman SM; Dixit J; Naik R; Diwakar RB; Satheesh CT; Shashidhara HP; Patil S; Gopinath KS; Kumar BS
Indian J Cancer; 2014; 51(4):531-7. PubMed ID: 26842186
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapies for metastatic colorectal cancer].
Kito Y; Yamazaki K
Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
[TBL] [Abstract][Full Text] [Related]
15. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
[TBL] [Abstract][Full Text] [Related]
16. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
17. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
[TBL] [Abstract][Full Text] [Related]
20. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
Modest DP; Stintzing S; Laubender RP; Neumann J; Jung A; Giessen C; Haas M; Aubele P; Schulz C; Boeck S; Stemmler HJ; Kirchner T; Heinemann V
Anticancer Drugs; 2011 Oct; 22(9):913-8. PubMed ID: 21795973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
